Compare iShares 7-10 Year Treasury Bond ETF (IEF) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 7-10 Year Treasury Bond ETF vs TG Therapeutics Inc — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $89.4 (market cap $41.13B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: iShares 7-10 Year Treasury Bond ETF is far larger — about 5× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 7-10 Year Treasury Bond ETF for 108 Days and TG Therapeutics Inc for 16 Days on average.
| IEF | TGTX | |
|---|---|---|
Market Cap | $41.13B | $8.16B |
Volume | 10,340,382 | 1,735,121 |
Sector | Fixed Income | Health |
52-Week High | $97.99 | $59.06 |
52-Week Low | $88.92 | $26.94 |
Typical Hold Time | 108 Days | 16 Days |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEF is trading at $89.45, up 0.38% with a bearish technical signal from moving averages. The ETF shows neutral oscillator readings with RSI at 52.94, while ADX indicates strong bearish momentum. Recent dividend payments of $0.31-$0.33 provide income support amid challenging bond market conditions. Key support sits at $89 with resistance at $90, creating a tight trading range.
The outlook remains cautious as Treasury yields near multi-decade highs create headwinds for bond ETFs. While current levels may offer entry points for income-focused investors, persistent inflation and Fed policy uncertainty pose significant risks. The bearish technical setup suggests continued pressure unless macroeconomic conditions improve.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
